Dutch research 61 items
Work from Amsterdam UMC (Stroes, Nurmohamed, Kaiser, Stiekema, Wiegman, de Boer), Erasmus MC (Roeters van Lennep, Kaiser) and Leiden, and the Dutch role in the EAS consensus and the ESC 2025 update.
Studies
- The 2022 EAS consensus statement on Lp(a) in ASCVD and aortic stenosis (Kronenberg, Mora, Stroes et al., EHJ 2022)
- IONIS-APO(a)Rx and the GalNAc-conjugated APO(a)-LRx: two dose-ranging trials (Viney et al., Lancet 2016)
- 2025 focused update of the 2019 ESC/EAS dyslipidaemia guidelines (Mach, Koskinas, Roeters van Lennep et al., EHJ 2025)
- Muvalaplin, the first oral inhibitor of Lp(a) formation: phase 1 (Nicholls et al., JAMA 2023)
- Lp(a) and oxidised phospholipids drive valve calcification activity and progression in aortic stenosis (Zheng et al., JACC 2019)
- Oxidised phospholipids on Lp(a) drive arterial wall inflammation and a primed monocyte response (van der Valk et al., Circulation 2016)
- High Lp(a) accelerates low-attenuation (necrotic core) plaque progression on serial CT angiography (Kaiser et al., JACC 2022)
- Potent Lp(a) lowering with apo(a) antisense reduces pro-inflammatory activation of monocytes (Stiekema et al., EHJ 2020)
- Arterial wall inflammation persists in high-Lp(a) patients despite 60 percent LDL-C lowering with evolocumab (Stiekema et al., EHJ 2019)
- One-time LDL-C, hs-CRP and Lp(a) screening predicts 20-year events in European men and women: EPIC-Norfolk (Kraaijenhof, Nurmohamed et al., EHJ 2025)
- Zerlasiran single and multiple doses in ASCVD patients: Lp(a) down 90 percent at 201 days after two doses (Nissen et al., JAMA 2024)
- Lp(a) in children with suspected familial hypercholesterolaemia (de Boer et al., EHJ 2023)
- Lp(a) is associated with the onset but not the progression of aortic valve calcification: the Rotterdam Study (Kaiser et al., EHJ 2022)
- Finding very high Lp(a): the case for routine assessment (Nurmohamed et al., Eur J Prev Cardiol 2022)
- Combined LDL-C, Lp(a) and hsCRP identify highest ASCVD risk across ethnicities, multiethnic HELIUS cohort of 15,676 (J Am Coll Cardiol 2026)
- Very high Lp(a) predicts earlier heart attack and 16-fold higher recurrent MI risk, matched cohort of 446 (JACC Adv 2026)
- Amsterdam UMC's decade-long serial CT scans show high Lp(a) drives more plaque, more low-density plaque and more pericoronary inflammation (JAMA Cardiol 2024)
- Very low Lp(a) raises new-onset diabetes and fatty liver risk in UK Biobank, but Mendelian randomisation finds no causal link (Atheroscler Plus 2024)
- Cascade screening yields elevated Lp(a) in 47% of first-degree relatives, a 7.4-fold higher odds than unrelated individuals, in 52,418 UK Biobank participants (JAMA Cardiol 2023)
- MFSD5 identified as a receptor mediating lipoprotein(a) uptake and calcification in heart valve cells, with variants linked to aortic stenosis (Circulation 2024)
- Genetically higher Lp(a) raises atrial fibrillation risk in Europeans but not in a Chinese cohort, a Mendelian randomisation meta-analysis of 2.1 million participants (Curr Probl Cardiol 2024)
- Lp(a) drives progressive carotid wall thickening in children with familial hypercholesterolaemia followed 20 years into adulthood, a Dutch cohort of 200 (Lancet Diabetes Endocrinol 2023)
- Every 50 mg/dL rise in Lp(a) raises cardiovascular death risk by up to 31%, a dose-response meta-analysis of 957,253 people across 75 studies (Eur J Epidemiol 2023)
- Pelacarsen cut Lp(a) by 80% in phase 2, letting 98% of patients reach target levels, as the 7,680-patient Lp(a)HORIZON outcomes trial enrolls, a JACC Focus Seminar (J Am Coll Cardiol 2021)
- Elevated Lp(a) risk fades when LDL cholesterol is below 2.5 mmol/L, an EPIC-Norfolk and Copenhagen City Heart Study analysis (Eur Heart J 2018)
- Lp(a) tracks with coronary plaque burden but not long-term mortality in established ASCVD, combined cohort of 798 (Eur J Prev Cardiol 2026)
- Global Lp(a) standardization nears reality with a mass-spectrometry reference method, review (Clin Chem Lab Med 2026)
- Elevated Lp(a) causes more diffuse coronary flow limitation, PIONEER IV substudy of 150 matched patients (Cardiovasc Revasc Med 2026)
- Mass-based and molar-based Lp(a) immunoassays are interchangeable, near-identically predicting coronary and aortic valve calcification, Rotterdam Study of 5,129 finds (Am Heart J 2025)
- Amsterdam UMC team finds Lp(a)-carried diacylglycerols drive monocyte inflammation via NLRP3, and pelacarsen lowers these specific lipids (Arterioscler Thromb Vasc Biol 2024)
- A faster LC-MS comparison method matches the Lp(a) reference measurement procedure, easing the shift to molar reporting units (Clin Proteomics 2024)
- One in five people of European ancestry has elevated Lp(a), and new RNA drugs can lower it more than 95%, a review by three leading Lp(a) researchers (Pharmacol Res 2023)
- Correcting LDL-C for genetically estimated Lp(a) reclassifies up to 9% of suspected FH patients as unlikely FH, in 1,504 Dutch referrals (Atherosclerosis 2023)
- Pelacarsen and olpasiran achieve up to 90% Lp(a) reductions, positioning routine Lp(a) testing as clinically essential, a review (Curr Opin Lipidol 2023)
- Statin therapy does not meaningfully change Lp(a), a Dutch meta-analysis of 39 trials and 24,448 participants (Eur J Prev Cardiol 2022)
- Lp(a) rises 22-43% from childhood to adulthood depending on lipid-lowering treatment, with 70% intra-individual variation, in 2,740 Dutch children (Atherosclerosis 2022)
- Lp(a) is linked to more vulnerable carotid plaque features, with sex-specific patterns, in the Dutch PARISK study of 182 patients (Atherosclerosis 2021)
- Elevated Lp(a) predicts higher coronary calcium scores in healthy relatives of patients with premature heart disease, a study of 937 family members (J Clin Lipidol 2018)
- Antisense therapy can cut Lp(a) by up to 90% in phase 1/2 trials, as three treatment approaches converge on the 'revenant' lipoprotein, a review (Eur Heart J 2017)
- Homozygous autosomal dominant hypercholesterolaemia doubles Lp(a) levels compared to heterozygous carriers, a Dutch study of 119 individuals (J Clin Lipidol 2017)
- Amsterdam UMC study finds high Lp(a) raises monocyte inflammation genes but not chromatin accessibility, pointing to a non-epigenetic mechanism (J Clin Lipidol 2025)
- Amsterdam UMC review finds cascade screening for elevated Lp(a) needs as few as 1.3 relatives tested per new case found (Curr Opin Lipidol 2024)
- Amsterdam UMC case-based review argues interventional cardiologists should measure Lp(a) routinely, given liberal but under-used guideline endorsement (Expert Rev Cardiovasc Ther 2024)
- Lipoprotein apheresis removes cell-derived extracellular vesicles alongside Lp(a), a possible extra mechanism behind its benefit (Sci Rep 2024)
- Lp(a) does not predict carotid intima-media thickness over 20 years in 88 children without familial hypercholesterolaemia (J Clin Lipidol 2024)
- Lp(a) is higher in children with homozygous familial hypercholesterolaemia than heterozygous FH or unaffected children, a Dutch cross-sectional study of 232 children (J Clin Lipidol 2023)
- A pan-European/North American comparison of Lp(a) guidelines converges on a risk calculator and lifetime screening, by three leading researchers (Curr Opin Lipidol 2022)
- Pelacarsen, olpasiran and SLN360 lower Lp(a) by up to 90%, with pelacarsen phase 3 outcome trial due in 2024, a review (Curr Atheroscler Rep 2022)
- The LPA gene IL-6 response elements make Lp(a) an inflammatory driver, not just a lipid particle, at levels above 125 nmol/L, a review (Atherosclerosis 2022)
- Lp(a) surges during COVID-19 hospitalisation and those with the biggest rise face a 3-fold higher risk of blood clots, a Dutch pilot study of 219 patients (Atherosclerosis 2022)
- High Lp(a) predicts major limb events after leg artery surgery for peripheral artery disease, in 384 Dutch patients (Atherosclerosis 2022)
- Lp(a)-lowering could become the third pillar of lipid therapy alongside LDL-C and triglycerides, a Dutch perspective on eradicating lipid-driven cardiovascular risk (Neth Heart J 2022)
- Lp(a) triggers a cascade from valve damage to calcification via autotaxin and NF-kB, a review of aortic valve stenosis mechanisms (Biomolecules 2019)
- Lp(a) does not predict carotid plaque in statin-treated familial hypercholesterolaemia, a Dutch study of 191 patients (Atherosclerosis 2015)
- Lp(a) impairs blood vessel dilation in healthy postmenopausal women, a Dutch study of 105 women (Atherosclerosis 2000)
- Twenty-year follow-up of Dutch familial hypercholesterolaemia cohort finds no link between Lp(a) and arterial stiffness (J Clin Med 2025)
- Amsterdam UMC case-control study finds Lp(a) above 50 mg/dL is nearly seven times more common in children with ischaemic stroke (Pediatr Blood Cancer 2024)
- Should children with high Lp(a) be treated with ASOs or siRNAs? A Dutch review argues yes, but only for those at highest cardiovascular risk (Expert Opin Pharmacother 2022)
- Could Lp(a) explain COVID-19 clotting complications? A Dutch-led team proposes IL-6-driven Lp(a) surges as a testable hypothesis (Curr Atheroscler Rep 2020)
- Proving Lp(a) lowering improves cardiovascular outcomes remains the field's next urgent challenge, a Dutch review of current Lp(a) therapies (J Lipid Res 2016)
Video and podcasts